LifeArc Co-Founded Company RQ Bio Entered into a License Agreement with AstraZeneca to Develop Monoclonal Antibodies Against SARS-CoV-2
Shots:
- RQ Bio to receive up front & milestones of ~$157M along with royalties. The agreement was supported through continued collaborations with the University of Oxford & LifeArc
- AstraZeneca gets an exclusive license globally for RQ Bio's early-stage mAbs against SARS-CoV-2 & obtains the right to exclusively license an additional mAbs against SARS-CoV-2. The collaboration combines RQ Bio’s expertise to develop neutralizing Ab therapy for SARS-CoV-2 & for other viral inf. diseases
- RQ Bio continues to develop treatments & preventative therapies, based on broad-spectrum mAbs that give immediate & long-lasting immunity to patients who are at risk of serious disease or death from viral inf.
Ref: PRNewswire | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
